These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32271432)

  • 1. USP3 promotes proliferation of non-small cell lung cancer through regulating RBM4.
    Liao XH; Wang Y; Zhong B; Zhu SY
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3143-3151. PubMed ID: 32271432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-597 inhibits NSCLC progression through negatively regulating CDK2 expression.
    Yu DJ; Li YH; Zhong M
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4288-4297. PubMed ID: 32373965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA TRERNA1 promotes malignant progression of NSCLC through targeting FOXL1.
    Luo DB; Lv HB; Sun XH; Wang Y; Chu JH; Salai AL
    Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1233-1242. PubMed ID: 32096153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA HOXA-AS2 regulates microRNA-216a-5p to promote malignant progression of non-small cell lung cancer.
    Cui TJ; Lin GS; Dai YM; Zheng JP; Chen Z; Chen Q; Zheng Y; Lin X
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):264-273. PubMed ID: 31389597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. USP3 promotes cisplatin resistance in non-small cell lung cancer cells by suppressing ACOT7-regulated ferroptosis.
    Tao R; Liu Z; Zhang Z; Zhang Z
    Anticancer Drugs; 2024 Jul; 35(6):483-491. PubMed ID: 38502867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-424-5p inhibits the development of non-small cell LCa by binding to ITGB1.
    Xu ZL; Zhang M; Chen SX; Qiu M; Zhang Q; Gao LP; Li JDX
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8921-8930. PubMed ID: 31696479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
    Gao BB; Wang SX
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA WT-AS inhibits metastatic ability of non-small cell lung cancer by regulating KLK13.
    Wang Y; Tan TZ; Wang LQ; Zhang K
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9429-9437. PubMed ID: 33015785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAGI1-IT1 stimulates proliferation in non-small cell lung cancer by upregulating AKT1 as a ceRNA.
    Zhang G; Chen HX; Yang SN; Zhao J
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):691-698. PubMed ID: 32016970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of LncRNA FOXC2-AC1 promoting lung cancer metastasis by regulating miR-107.
    Wu XF; Lu JT; Chen W; Wang N; Meng JC; Zhou YH
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):690-698. PubMed ID: 30720176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of N-Acetylglucosaminyltransferase GCNT3 by miR-302b-3p Decreases Non-Small Cell Lung Cancer (NSCLC) Cell Proliferation, Migration and Invasion.
    Li Q; Ran P; Zhang X; Guo X; Yuan Y; Dong T; Zhu B; Zheng S; Xiao C
    Cell Physiol Biochem; 2018; 50(3):987-1004. PubMed ID: 30355927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA BX357664 inhibits the proliferation and invasion of non-small cell lung cancer cells.
    Yang J; Du YM; Li B
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):660-669. PubMed ID: 30720174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA HOST2 enhances gefitinib-resistance in non-small cell lung cancer by down-regulating miRNA-621.
    Chen ZY; Liu HY; Jiang N; Yuan JM
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9939-9946. PubMed ID: 31799663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiRNA-621 inhibits the malignant progression of non-small cell lung cancer via targeting SIX4.
    Zhang M; Shi H; Zhang C; Zhang SQ
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4807-4814. PubMed ID: 31210312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CLK2 promotes occurrence and development of non-small cell lung cancer.
    Liu B; Kong X; Wang R; Xin C
    J BUON; 2021; 26(1):58-64. PubMed ID: 33721432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-19a promotes proliferative and migratory abilities of NSCLC cells by inhibiting PTEN expression.
    Shi J; Han Y; Lin D; Wang K; Liu B; Gao C
    J BUON; 2019; 24(3):955-962. PubMed ID: 31424647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-146-5p Promotes Pulmonary Artery Endothelial Cell Proliferation under Hypoxic Conditions through Regulating USP3.
    Zhang W; Qi Y; Wu B
    Dis Markers; 2021; 2021():3668422. PubMed ID: 34917199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LINC00511 promotes the progression of non-small cell lung cancer through downregulating LATS2 and KLF2 by binding to EZH2 and LSD1.
    Zhu FY; Zhang SR; Wang LH; Wu WD; Zhao H
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8377-8390. PubMed ID: 31646568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA HANR aggravates the progression of non-small cell lung cancer via mediating miRNA-140-5p.
    Li SJ; Wu YX; Liang YH; Gao Y; Wu AB; Zheng HY; Yang ZX
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):704-711. PubMed ID: 32016972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of lncRNA FEZF1-AS1 in promoting the occurrence and development of oral squamous cell carcinoma through targeting miR-196a.
    Xu L; Hou TJ; Yang P
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6505-6515. PubMed ID: 31378890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.